Blockade of the CD40-CD40L and CD80/CD86-
Introduction
The immune response directed against Ad vectors represents a major limitation for their use in gene therapy applications which require repeated administrations. Transduction of target tissues such as the liver or the lung by non-replicative Ad vectors is inflammatory and induces humoral and cellular responses involving CD4 + and CD8
+ T cells which can be directed against adenoviral proteins and the transgene product. [1] [2] [3] [4] Cytotoxic T lymphocytes (CTLs) directed against immunogenic transgenes have been shown to limit the persistence of transduced cells. 3, 4 CTLs directed against adenoviral proteins have also been suspected to affect the long-term persistence of the viral genome by destroying transduced cells, due to leaky expression of late viral genes. 5 However, expression of a non-immunogenic transgene can be relatively stable and long-lasting, suggesting that anti-Ad CTLs only play a minor role in the elimination of transduced cells. [2] [3] [4] The humoral response to Ad proteins constitutes the main obstacle to vector readministration. repeated systemic administrations do not achieve efficient re-transduction of the target tissues due to the production of circulating neutralizing antibodies (NAbs). 1, [6] [7] [8] [9] In mouse models, transient depletion or blocking of the CD4 + T cell population decreases the production of anti-Ad antibodies (Abs) and permits vector readministration. 10, 11 However, these strategies induce profound immunosuppression, potentially detrimental to patients with genetic diseases. Furthermore, it may not apply to primates as suggested by a recent study showing that blocking of CD4 + cell responses did not decrease the humoral response following vector instillation in the lung of Rhesus monkeys. 12 Ideally, a non-depleting treatment inducing only transient suppression of the immune response against the virus should be achieved. Such approach should not lead to immunological tolerance to Ad proteins, since patients must remain capable of responding against infection by wild-type Ad.
Antigen presentation leads to productive lymphocyte activation when co-stimulatory signals are delivered by the binding of surface molecules such as CD40, CD80/B7.1 and CD86/B7.2, present on antigenpresenting cells (APCs) and up-regulated in the context of inflammation, with their ligands on T cells. [13] [14] [15] In the absence of co-stimulation, antigen recognition by the TCR has been shown to induce T cell anergy or unresponsiveness. [15] [16] [17] [18] [19] CD28 and CTLA4 present on the surface of T cells can bind indifferently CD80 and CD86 molecules on APCs, but deliver opposite signals: the binding of CD28 contributes to T cell activation while CTLA4, which is induced later during activation, down-regulates the T cell response and participates in the induction of peripheral tolerance. [20] [21] [22] [23] [24] [25] CD40L/CD154 is the ligand for CD40 and is transiently induced on T cells upon antigen recognition. Stimulation of CD40 molecules, present on the surface of B cells, by CD40L plays a crucial role in the development of the humoral response, including Ig isotype switching and regulation of B cell proliferation. In addition, activation of APCs through CD40 results in increased expression of CD80 and CD86 co-stimulatory molecules. 13 Importantly, CD40 signalling in dendritic cells induces their functional maturation by up-regulating the expression of MHC and co-stimulatory molecules on their surface and the secretion of cytokines, such as IL-12. 26 In mouse models, a large body of evidence has suggested that the blockade of either or both of the CD40-CD40L and B7-CD28 co-stimulatory pathways can inhibit the development of an immune response against Ad vectors.
27-30 Cellular and humoral reponses against Ad were partially inhibited by treatment with anti-CD40L mAb, which allowed vector readministration to the lungs in mice and also in primates. [29] [30] [31] Most encouraging results have been obtained in the study of Kay et al, 28 where simultaneous blocking of CD40 and of B7 molecules using an anti-CD40L mAb and a CTLA4-Ig fusion molecule resulted in successful secondary Ad-mediated gene transfer to the mouse liver. These results showed that blockade of both co-stimulatory pathways is necessary to efficiently inhibit the anti-Ad immune response following systemic administration.
Because the CTLA4-Ig molecule binds both CD80 and CD86, studies using this molecule do not allow the respective contribution of B7 molecules to the immune response against Ad to be deciphered. The requirement of blocking either or both of CD80 and CD86 costimulatory molecules in addition to CD40-CD40L interaction to achieve optimal suppression of the immune response remains to be resolved. Distinct and seemingly contradictory roles have been reported for CD80 and CD86 molecules notably in the context of autoimmune diseases and tolerance induction. [14] [15] [16] [17] 25, [32] [33] [34] [35] Transgenic mice overexpressing CD80 on mature B cells make reduced humoral responses to T-dependent antigens. 36 Allowing CTLA4 engagement by CD80 has been shown to inhibit T cell activation in the absence of CD28. 24 Since CD80 is up-regulated later than CD86 on the surface of activated APCs, 15, 17 it could be hypothesized that leaving CD80 molecules available could favor their interaction with CTLA4 on T cells and thereby contribute to down-regulation of T cell responses. CTLA4 shows around 10-fold greater affinity for B7 molecules than CD28 does, which is reflected by the capacity of the CTLA4-Ig fusion protein to inhibit CD28-mediated T cell responses.
To address these points and attempt to down-regulate the immune response against Ad with maximal efficacy, we investigated the effect of transiently blocking CD40L, CD80 and/or CD86 at the time of first vector administration. The effect of all combinations of blocking mAbs on humoral and cell-mediated immune responses to an Ad vector (Ad-hFIX) injected systemically were examined. The efficiency of secondary gene transfer was evaluated 4 weeks later, following administration of an Ad vector encoding a second reporter transgene (Ad-h␥IFN) in the absence of a costimulation-blocking treatment. The immune response was further analyzed after readministration to investigate the effect of the costimulation-blocking treatment on the capacity to elicit a posteriori an immune response against Ad.
Results

Abrogation of the humoral response against Ad vector by blocking CD40L, CD80 and CD86
We first tested the effect of all combinations of blocking mAbs directed against CD40L, B7.1/CD80 and B7.2/CD86 on the anti-Ad immune response when injected at the time of first vector administration. Figure  1 describes the experimental scheme comprising 10 groups of 10 C57Bl/6 mice each. At day 0, an Ad vector encoding human factor IX (Ad-hFIX, 10 9 IU/mouse) was injected into the tail vein of animals treated with the blocking mAbs that were injected intraperitoneally. We chose to use the C57Bl/6 mouse strain because it was shown to be tolerant to the hFIX transgene product after i.v. injection of Ad-hFIX, resulting in sustained hFIX expression in the serum. 4, 37 Levels of this transgene product in the circulation therefore reflect the number of transduced cells in the targeted tissues. A second vector, encoding human ␥IFN (Ad-h␥IFN, 10 9 IU/mouse), was administered intravenously 4 weeks later (day 28). Dosage of circulating h␥IFN was used as read-out to assess the efficiency of readministration.
The humoral response against Ad was measured following the first administration of Ad-hFIX and the efficiency of immunosuppression was evaluated by comparing mouse groups that received the mAbs to the untreated group (Figure 1b, without immunosuppressive treatment) and to naive animals (group 10, injected with PBS only). Figure 2 shows the kinetics of appearance of total anti-Ad Abs, as determined by Elisa. Figure 3 shows the titration of antiAd NAbs at day 27 after injection, 1 day before administration of the second vector. Anti-CD80 or anti-CD86 mAbs used alone did not affect the humoral response (groups 2 and 3, Figures 2 and 3) . In contrast, treatment with anti-CD40L partially reduced the production of antiAd Abs (group 1, Figures 2 and 3 ), as reported in former studies. 29, 30 It should be noted that the anti-CD40L mAb had to be injected at days Ϫ2, 0, +3 and +6 to show an
Figure 3 The neutralizing Ab response against Ad vector is totally abrogated at day 27 in mice treated with anti-CD40L + -CD80 + -CD86 upon first Ad vector administration, and strongly inhibited with anti-CD40L + -CD86 or anti-CD80 + -CD86. Ad-specific NAb were titrated 27 days after administration of the first vector Ad-hFIX (1 day before injection of the second Ad vector, Ad-h␥IFN, at day 28). Each graph includes a positive control (pooled serum from immune mice, bold curves with black squares) and a negative control (pooled serum from naive mice, bold curves with black circles). Control groups show the titration curves obtained from animals injected with Ad-hFIX in the absence of costimulation-blocking mAbs (immunized, upper right graph), or from untreated mice (naive, lower right graph).
Gene Therapy effect (group 1), since when this mAb was given only at days -2 and 0, no significant reduction in anti-Ad NAb titers was observed (data not shown). Therefore, CD40-CD40L interactions must be blocked for a few days after administration of the Ad vector in order to decrease immune stimulation.
While blocking of CD86 alone did not show any inhibitory effect (compare groups 2 and 8, Figures 2 and 3) , the combination of anti-CD86 mAb with either anti-CD40L or anti-CD80 mAbs resulted in a strong reduction in antiAd Abs (groups 4 and 5, Figures 2 and 3 ). These two combinations appeared equally potent in dampening the humoral response, since only low to intermediate NAb titers were observed at day 27 (groups 4 and 5, Figure  3) . However, as shown in Figure 3 (group 7), the most efficient immunosuppression was achieved using the combination of all three blocking mAbs anti-CD40L + -CD80 + -CD86, resulting in a complete lack of anti-Ad NAbs 4 weeks after injection. In another experiment, mice exposed to the same regimen were found not to develop an anti-Ad humoral response for at least 3 months (result not shown).
Efficiency of Ad vector readministration
As shown in Figure 4 , administration of the second vector (Ad-h␥IFN) 28 days after the first injection and costimulation blockade resulted in levels of h␥IFN in the serum that were inversely correlated with pre-existing anti-Ad Ab titers. Like preimmunized animals (group 8, Figure  4 ), mouse groups treated with anti-CD80 or anti-CD86 mAb alone (groups 2 and 3, Figure 4 ) did not have detectable levels of the transgene product in their serum. Groups 1 (treated with anti-CD40L only) and 6 (treated with anti-CD40L + -CD80), which showed a slight reduction in anti-Ad NAb titers before readministration, had only low levels of circulating h␥IFN. Groups treated with the anti-CD86 mAb in combination with either anti- 
d.) at day 3', 7', 14', 21' and 42' post-readministration, in the groups previously treated or not with blocking mAbs against CD40L, CD80 and/or CD86 upon first vector administration (Ad-hFIX at day 0). Without costimulation blockade, readministration is totally inefficient (group 8) while mice treated with anti-CD40L + -CD80 + -CD86 show the same kinetics of transgene expression as naive mice injected for the first time with Ad-h␥IFN (group 10).
CD40L or anti-CD80 mAb (groups 4 and 5, Figure 4 ) displayed levels of circulating h␥IFN approximately one half log lower than naive animals (group 10, Figure 4 ). Mice that had been treated with all three blocking mAbs at the time of first vector injection exhibited serum levels of h␥IFN as high as those observed in animals that received only the second vector (compare groups 7 and 10, Figure 4 ). These results show that blocking all three CD40L, CD80 and CD86 costimulatory molecules abrogates the humoral response against Ad and allows vector readministration with the highest efficiency.
Blocking of the immune response is transient
In all mouse groups, total anti-Ad Abs as measured by Elisa increased following injection of the second vector in the absence of costimulation blockade (data not shown). As shown in Figure 5 , 15 days after the second injection (day 15'), NAb titers in groups 4, 5 and 7 (treated with anti-CD80 + -CD86, anti-CD40L + -CD86 or the three blocking mAbs, respectively) were similar to those of group 10 that received only the second vector, reflecting a primary humoral response. Groups 1 and 6, in which the primary immune response had been decreased by treatment with anti-CD40L in the presence or absence of anti-CD80 mAb, exhibited intermediate NAb titers (Figure 5 ). Groups 2 and 3, in which treatment with anti-CD80 or anti-CD86 mAbs alone did not inhibit the humoral response against the first vector, had high levels of anti-Ad NAbs at day 15' similarly to the preimmunized group, suggesting a secondary humoral response upon readministration (not shown).
These results show that inhibiting the humoral response with blocking mAbs against CD40L, CD80 and CD86 did not lead to the deletion or inactivation of Adreactive lymphocytes. The capacity to respond to adenoviral antigens is intact 1 month after the mAb treatments, that are therefore non-tolerogenic in these conditions.
Inhibition of Ig class switching
We next sought to analyze the IgM to IgG isotype switch in the different mouse groups. In all groups characterized by efficient immunosuppression and readministration, levels of serum anti-Ad IgG were low or undetectable 2 weeks after the first administration ( Figure 6 , IgG at day 13 in groups 1, 4, 5, 6 and 7). In contrast, IgM (predominating in a primary response) were detected in all groups, even in those that were efficiently immunosuppressed ( Figure 6 , IgM at day 13). This shows that our Elisa test for the detection of total anti-Ad Abs (Figure 2 ) did not recognize IgM, and that groups 4, 5 and 7 actually produced low levels of Abs of the IgM isotype before readministration. Two weeks after the second injection in the absence of costimulation blockade, IgG/IgM ratios were increased in all mouse groups ( Figure 6 , day 14'). In groups 4, 5 and 7, IgG levels at day 14' after readministration were similar to those observed in naive animals 2 weeks after the first administration (group 8 at day 13 or group 10 at day 14').
Blocking CD40L, CD80 and CD86 upon administration of the first vector blocks the switch in Ig isotype. IgM do not seem to influence the efficiency of Ad vector readministration, since mouse group 7 (treated with the three blocking mAbs, but showing some anti-Ad IgM, Figure  6 ) showed similar expression and kinetics of the second transgene as compared with naive animals (group 10, Figure 6 , absence of IgM). Moreover, we found that these IgM were unable to neutralize adenoviral transduction of 293 cells in vitro (Figure 3 ).
Figure 5 Blocking costimulatory molecules upon first Ad vector administration does not lead to immunological tolerance. Fifteen days after injection of the second vector (Ad-h␥IFN), neutralizing anti-Ad Abs were titrated in groups that showed partial or total inhibition of anti-Ad humoral response after the first vector administration. Each graph includes a positive control (pooled serum from immune mice, bold curves with black squares) and a negative control (pooled serum from naive mice, bold curves with black circles). Control graphs show titration curves obtained from groups injected with Ad-hFIX in the absence of costimulation-blocking mAbs and readministered with Ad-h␥IFN (group 8), or from naive mice injected for the first time with Ad-h␥IFN (group 10).
Effect of treatment with anti-CD40L, -CD80 and -CD86 mAbs on the cellular immune response against Ad
In a second experiment, we evaluated the effect of the blocking mAbs anti-CD40L, -CD80 and -CD86 on the cellular arm of the immune response. To this end, groups of 20 mice were treated with the mAb combinations that were the most potent in repressing the humoral response against Ad. The effect of these blocking mAb combinations on the repression of the humoral response were similar in this experiment to the one described above (result not shown). Spleens were taken from five mice per group at days 14 and 27 after administration and the number of m␥IFN-producing splenocytes was determined in Elispot assays that used Ad as antigen. The remaining animals were used to measure the anti-Ad cellular response at days 3' and 14' following administration of the second vector.
The cell-mediated immune response was inhibited following Ad vector administration in the presence of the blocking mAb combinations (Figure 7) . Before readministration, at day 27, groups treated with either anti-CD80 + CD86, anti-CD40L + CD86 or anti-CD40L + CD80 + CD86 had the same numbers of Ad-specific, m␥IFN-producing splenocytes as found in the naive controls ( Figure  7 ). In the group treated with anti-CD40L alone, the number of Ad-reactive splenocytes was only partially reduced when compared with the control group (no immunosuppressive treatment).
After administration of the second vector, mice treated with anti-CD40L +/Ϫ anti-CD86 developed comparable numbers of m␥IFN-producing splenocytes as in the preimmune group (group 8, Figure 7 ), higher than in the naive group (group 10, Figure 7) . This raises the possiGene Therapy bility that a cellular response had actually been initiated before readministration, but remained undetected in the groups treated with anti-CD40L + anti-CD86. In contrast, animals treated either with anti-CD80 + -CD86 or with anti-CD40L + -CD80 + -CD86 (groups 4 and 7, Figure 7 ) mounted an anti-Ad cellular response which was comparable to that observed in the naive mouse group, at day 3' and at day 14'. Therefore, for the cell-mediated as well as for the humoral response, these groups behaved as if they had not been primed upon administration of the first Ad vector.
The presence of immune cell infiltrates in the liver, the main target organ following systemic injection of Ad vectors, was found to correlate with the cellular response measured by ELISPOT. In particular, perivascular infiltrates of CD4 + lymphocytes were rarely detected 2 weeks after injection of the first Ad vector in the mouse groups treated with anti-CD80 + -CD86 or with the three blocking mAbs, while they were frequent in the liver of untreated animals or of mice treated with anti-CD40L only (results not shown).
Altogether these data show that transient blocking of CD40L, CD80 and CD86 inhibits the development of a cellular immune response against the Ad vector. This treatment does not seem to induce the depletion or inactivation (anergy) of Ad-reactive lymphocytes, since the cellular response observed following readministration in the absence of costimulation blockade is comparable in pre-treated and in naive mice, in terms of m␥IFN-producing, Ad-specific splenocytes. Rather, it seems to prevent the initiation of the immune response against Ad, which could be considered as temporary 'ignorance'.
Figure 6 Reversible inhibition of IgM to IgG isotype switch by treatment with costimulation-blocking mAbs. IgM and IgG directed against the Ad vector were measured by ELISA at day 13 following first administration of Ad-hFIX in the mouse groups treated or not with blocking mAbs against CD40L, CD80 and/or CD86 (upper panel) and at day 14' following administration of the second vector Ad-h␥IFN (lower panel).
Expression of non-immunogenic transgene hFIX is not affected by the development of a specific cellular immune response against Ad after first vector administration
In both experiments performed, the kinetics of first transgene hFIX expression in the serum was comparable in all mouse groups, whether treated or not with the costimulation-blocking mAbs (Figure 8) . After peaking at day 15, hFIX expression stabilized at around 10 g/ml for at least 28 days after readministration (not shown). Mice of the C57Bl/6 strain are known to be tolerant to the hFIX transgene product after i.v. injection of Ad-hFIX. 4, 37 As shown above, the cell-mediated immune response against the Ad vector is drastically if not totally abrogated in mice treated with blocking mAbs anti-CD40L, -CD80 and -CD86 (Figure 7) . Thus, we have observed similar persistence of transgene expression in animals characterized by the development or the absence of Ad-specific m␥IFN-secreting lymphocytes. This suggests that at least in C57Bl/6 mice injected with an Ad vector, the persistence of expression of a non-immunogenic transgene is not dependent on the development of a specific cellular immune response against Ad.
Figure 7 Reversible inhibition of the cellular immune response against Ad vector in mice treated with blocking mAbs to CD40L, CD80 and/or CD86. Splenocytes from five mice per group were analyzed in ELISPOT assays for the detection of Ad-reactive, m␥IFN-producing cells at days 14 and 27 following the first administration of Ad vector with or without anti-CD40L, -CD80 and/or -CD86 mAbs, and at days 3' and 14' following second vector injection in the absence of costimulation-blocking treatment (days 31 and 42 after the first administration).
Figure 8 Expression of non-immunogenic transgene hFIX is not affected by the development of a specific cellular immune response against Ad after first vector administration. Levels of hFIX transgene product in the serum were measured following injection of first vector Ad-hFIX in the different mouse groups, characterized by the presence or absence of a cellular immune response against Ad. Data shown are from one of two experiments giving similar results.
Discussion
The present work shows that transient blocking of the interactions mediated by CD80, CD86 and CD40L with their ligands is necessary to fully abrogate humoral and cellular immune responses otherwise induced by systemic injection of an Ad vector. While injection of a second Ad vector was totally ineffective in untreated, pre-immunized mice, treatment with the three blocking mAbs at the time of first vector injection allowed readministration with the same efficiency as in naive mice, as determined by the levels of the second transgene secreted in the serum. When used individually, none of the mAbs anti-CD40L, -CD80 or -CD86 could affect the immune response to Ad, despite a weak effect observed with anti-CD40L. Blocking of CD86 along with any of the two other costimulatory molecules resulted in strong, but incomplete, inhibition of the immune response. This indicates that CD86/B7.2 plays a central role in the immune response against the Ad vector. When anti-CD86 was used in combination with anti-CD40L or anti-CD80 at the first administration, injection of a second Ad vector resulted in levels of transgene expression that were about half an order of magnitude lower than those found in naive mice. One month after treatment, animals were able to develop a normal immune response to an Ad vector. This suggests that repeated administrations of Adderived vectors can be envisaged with this strategy, at least for gene therapy applications in which short-term immunosuppression does not compromize the patient's status.
We chose the C57Bl/6 mouse strain in our model, because it has been shown to be tolerant to hFIX encoded by Ad vectors injected systemically. 4, 37 We found no difference in the kinetics of hFIX expression between the different groups, whether or not they were treated with blocking mAbs and were shown to develop Ad-reactive, m␥IFN-producing lymphocytes. This indicates that in C57Bl/6 mice injected for the first time with an Ad vector, the development of a specific cellular immune response against Ad does not modulate the kinetics of expression of a non-immunogenic transgene. The cellular immune response includes CD8 + cells, which have been previously implicated in the rapid decline in transgene expression. [1] [2] [3] [27] [28] [29] [30] In mouse models in which the transgene product is immunogenic, expression was found to persist over a longer time period when vectors were administered in the context of costimulation blockade. [27] [28] [29] 38, 39 Our results suggest that in these studies, the prolonged transgene expression may be due to inhibition of the immune response against the transgene product rather than against the Ad vector.
The use of a blocking CTLA4-Ig fusion molecule (binding to both B7 molecules) along with an anti-CD40L mAb was shown to be a powerful means to inhibit the specific immune response triggered after intravenous injection of an Ad vector. 28 Blocking only the CD40L/CD40 pathway is sufficient to prevent the development of a humoral response following Ad vector administration in the lung, but insufficient when the vector is injected systemically. [27] [28] [29] [30] [31] In the latter situation and as reported here, blocking both CD40/CD40L and B7-mediated interactions is necessary to inhibit the immune response. However, in the study of Kay et al, 28 it was found that treatment with CTLA4Ig could not inhibit the Gene Therapy immune response to the Ad vector so as to allow readministration, even partially, after 8 weeks. In our study, the combination of anti-CD80 + -CD86 efficiently downregulated the anti-Ad immune response and readministration at day 28 was efficient, though not totally so. While this discrepancy may also reflect a strain-specific difference, it suggests that anti-CD80 + anti-CD86 mAb may be more effective than CTLA4Ig for blocking the immune response to Ad.
Blocking the interactions of both CD80 and CD86 with their ligands produces a strong inhibitory effect on the anti-Ad immune response. Thus, CD40-CD40L interaction cannot drive efficient humoral or cellular responses against the Ad vector in the absence of B7 molecules. Complementary functions have been described for the B7 molecules and the CD40-CD40L pathway in the costimulation of T cell responses, CD40L-mediated interactions playing a role in the maintenance of T cell responses, while CD28/B7 interactions are required at their initiation. 13, 14, 40, 41 This correlates with the observation that treatment with anti-CD40L alone results in a very limited decrease of the immune response. The immune response following systemic injection of the Ad vector was significantly inhibited only when anti-CD40L was combined with the anti-CD86 mAb. In the presence of anti-CD40L + -CD80 + -CD86, both humoral and cellular responses against the first Ad vector were fully abrogated. The only detectable response was the secretion of IgM, which is known to occur independently of CD40-CD40L interaction. 13 IgGs were totally absent, as a consequence of the essential roles of CD40/CD40L and of B7/CD28 on Ig isotype switching. 13, 42 While CD80 has been described as having an activating effect on T cell responses, studies reporting the phenotype of CD80-transgenic mice, which show markedly impaired immune response, 36 and the exacerbation of disease caused by the anti-CD80 blocking mAb in the NOD mouse model 34 suggested that this B7 molecule may also have a down-regulatory function. 14, 15 In our study, leaving CD80 molecules free in order to favor their interaction with CTLA4 receptors on T cells did not result in stronger inhibition of the immune response. Since CTLA4 is normally induced on the surface of activated T cells following binding of CD28, 23 it is possible that lack of CD28 stimulation by CD86 may result in lack of CTLA4 expression (which would then not be available for interaction with CD80). Alternatively, early CD80 expression on APC (or T cell) surfaces may be sufficient to stimulate CD28 and up-regulate T cell responses.
Blocking of either CD80 or CD86 is ineffective in decreasing the immune response triggered by Ad vector administration. However, CD86 stands as the pivotal B7 molecule for the development of the anti-Ad immune response. Blocking of CD80 along with the CD40-CD40L pathway has little inhibitory effect on the anti-Ad immune response, showing that CD86 may compensate almost completely for the absence of CD40L-and CD80-mediated interactions. In contrast, CD80 alone is a very weak co-stimulator of the immune response to Ad vector, as shown in mice treated with mAbs blocking CD86 and CD40-CD40L interactions: the latter mAb combination dramatically inhibits both humoral and cellular responses, resulting in fairly efficient readministration of Ad vector. However, the role of CD80 as a costimulator is reflected by the fact that while the anti-CD86 mAb alone has absolutely no effect on the immune response, additional blocking of CD80 dramatically down-regulates this response. Overlapping as well as complementary functions have indeed been reported for B7 molecules in T cell activation. 14, 15, 17, 32, [42] [43] [44] [45] T cell stimulation in the absence of a second signal provided by B7/CD28 or CD40/CD40L interactions has been shown to induce a state of anergy. [16] [17] [18] [19] Allograft rejection can be efficiently inhibited by blocking B7 molecules and CD40L for a limited time period following grafting, suggesting that tolerance can be achieved using this strategy. 40, 46, 47 In gene therapy applications, it would be problematic to induce long-term tolerance to an Ad-derived vector, since this would render patients unable to mount a response against infection by wild-type Ads. The fate of Ad-reactive lymphocytes in the context of costimulation blockade is therefore an important question. When treated mice were readministered a second Ad vector, they developed humoral and cellular responses that were of similar amplitude as animals injected for the first time with the same vector. This suggested that the Ad-reactive lymphocyte population was neither depleted nor inactivated following antigen encounter in the absence of costimulation. It appears unlikely that anergy is induced in our system, even though an anergic state might be reversed upon readministration of Ad vector in the presence of costimulatory molecules and of inflammatory cytokines. Most importantly, in our study, the observation that 1 month after treatment, animals showed no alterations in the immune response to Ad suggests that costimulation blockade in our system does not result in tolerance to Ad, but rather in ignorance.
Transient blockade of B7/CD28 and CD40/CD40L using mAbs fully inhibits the development of immunity to an Ad vector injected systemically, resulting in a lack of both anti-Ad NAb formation and cell-mediated responses. Consequently, an Ad vector can be readministered with the same efficacy as in naive mice. Our study has further dissected the respective roles of B7 molecules in the development of the immune response to the Ad vector, showing that both CD80 and CD86 exert a particular stimulatory function on humoral and cellular responses. Although we found that their roles were complementary, CD86/B7.2 stands as the main player in the development of the immune response against current Ad vectors designed for gene therapy applications.
Materials and methods
Hybridoma culture and production of mAbs GL1 (anti-CD86), 16.10A1 (anti-CD80) and MR1 (anti-CD40L) hybridomas were kindly provided by Dr Peter Van Kooten (Utrecht, Faculty of Veterinary Medicine). These mAbs have been widely used in costimulationblockade experiments. 24, 25, [28] [29] [30] 34, 38, 40, 45, 48 and GL1 and 1610A1 have been shown to block equally well CD86 and CD80, respectively. 48 Hybridomas were cultured in Integra CL350 flasks (Integra Biosciences, Cergy le Haut, France). Viable cells (8 × 10 6 ) were inoculated in the cultivation chamber containing 5 ml of DMEM supplemented with 4 mM glutamine, 4.5 g/l glucose, non-essential aminoacids (Life Technologies, Paisley, UK), sodium pyruvate (Sigma, St Louis, MO, USA), 20% FCS (Sigma) for MR1 and 16.10A1, 15% FCS for GL1. A volume of 125 ml of DMEM without FCS was added in the nutrient compartment. Cells were diluted and the medium renewed every 3 days. MAbs were purified from the culture supernatants using AFFI-T Thiophilic Agarose (KEM-EN-TEC, Copenhagen, Denmark) following the procedure described by the manufacturer. The eluted fractions were dialyzed overnight against PBS (Sigma) in a sterile dialysis cassette (Slide-A-Lyser 10, Pierce, Rockford, ME, USA). MAb concentrations were determined by measuring the absorbance at 280 nm. The quality of the products was assessed by controlling the absence of endotoxin contamination and performing SDS-Page gel (mini-gel NOVEX, San Diego, CA, USA).
Recombinant Ad vectors
All viral genomes derived from Ad serotype 5 were first constructed as infectious plasmids by homologous recombination in Escherichia coli as described. 49 They were deleted of viral E1 and E3 regions. Expression cassettes were inserted in place of the E1 region, in sense orientation. AdTG9397 (Ad-hFIX) contained the cDNA of human factor IX (hFIX) under the control of the human CMV promoter and followed by the SV40 polyadenylation signal. Vector AdTG13378 (Ad-h␥IFN) comprises the cDNA of human ␥IFN preceded by the CMV promoter and a ␤globin/IgG chimeric intron and followed by a bovine growth hormone polyadenylation signal. For the generation of viruses, the viral genomes were released from the respective recombinant plasmids by PacI digestion and transfected into 293 cells. 49 Virus propagation, purification and titration of the viral particles were carried out as described previously. 50, 51 For each virus preparation, the concentration of infectious units (IU) was measured by indirect immunofluorescence of the viral DNA-binding protein. 51 Purified virus was stored in viral storage buffer containing 1 M sucrose, 10 mM Tris-HCl (pH 8.5), 1 mM MgCl 2 , 150 mM NaCl, 0.005% Tween 80.
Animal studies C57Bl/6 female mice were purchased from Iffa Credo (l'Arbresle, France). Mice were maintained in our specific-pathogen-free animal facility and used at 7 weeks of age. MAbs (100 g anti-CD80, 250 g anti-CD86 and 100 g anti-CD40L at days -2 and +3; 100 g anti-CD80, 250 g anti-CD86 and 200 g anti-CD40L at day 0; and 100 g anti-CD40L at day +6) were mixed and diluted in PBS (Sigma), such that a volume of 100 l was injected intraperitoneally. Ad vectors were diluted in the viral storage buffer described above. 10 9 IU in a volume of 100 l were injected into the tail vein of mice. Ad-hFIX was administered at day 0 of the experiment and readministration of the second vector (Ad-h(IFN) was performed at day 28 (see Figure 1) . Ocular punctions were done every week for the analysis of anti-Ad Abs and transgene expression in the serum. At the indicated time-points (Figure 7 ), mice were killed and their spleens were used in ELISPOT assays.
Dosage of transgene products in the serum
The concentration of hFIX protein in mouse serum samples was determined using a commercial enzymelinked immunosorbent assay (ELISA) (Asserachrom, Diagnostica Stago, Asnières, France). The concentration of hIFN␥ was measured using an ELISA assay (Duoset hIFN␥, R&D Systems, Minneapolis, MN, USA) following the manufacturer's instructions.
Measurement of total anti-Ad Abs
Levels of total anti-Ad Abs were measured by ELISA. Ninety-six-well plates were coated overnight at 4°C in 100 l of buffer (200 mM NaHCO 3 , 80 mM Na 2 CO 3 , pH 9.5) containing UV-inactivated Ad-LacZ (10 8 viral particles). Wells were washed five times with a buffer composed of PBS, 0.1% Tween 20 and 10 mM EDTA, saturated with 150 l of 3% BSA in PBS, rinsed once and incubated with serial dilutions of serum (1/200 to 1/25 600) for 2 h at room temperature. Wells were washed four times. 100 l per well of a peroxidase-conjugated goat anti-mouse IgG+M (H+L), an anti-mouse IgG or an antimouse IgM (Jackson Immunoresearch Laboratories, West Grove, PA, USA) (1/5000 dilution) were added and incubated for 1 h at room temperature. After washing, 100 l of substrate solution (0.05 M citric acid, 0.05 M sodium acetate, 1% tetramethylbenzidine (TMB, Sigma), 0.015% H 2 O 2 ) was added and the reaction was stopped by adding 100 l per well of 0.8 M H 2 SO 4 . Absorbance was measured at 450 nm. Results shown represent OD values of sera diluted at 1/400 and normalized according the absorbance obtained using standard immune sera.
Titration of anti-Ad NAbs
NAbs were titrated by measuring the ability of serum dilutions to inhibit infection of 293 cells by Ad-LacZ. 293 cells (10 4 per well) in 96-well plates were cultured in DMEM medium supplemented with 10% FCS, for 24 h at 37°C, 5% CO 2 . Serial dilutions (1/10 to 1/20 480) of decomplemented mouse sera (15 min at 56°C) were preincubated for 1 h with Ad-LacZ in PBS containing 0.1% BSA and added to 60-70% confluent cells. Control sera from naive or immune mice were tested on each plate. After incubation for 16 h at 37°C, 5% CO 2 , ␤-gal activity was determined by washing the wells with PBS, lysing the cells in 0.5 % Triton X-100, 6 mM Na 2 HPO 4 , 4 mM NaH 2 PO 4 , 10 mM KCl, 0.1 mM MgSO 4 , 50 mM ␤-mercapto-ethanol, 170 g/ml 4-methyl-umbelliferyl ␤-D galactoside (Sigma) and measuring fluorescence at 340/460 nm (Victor, Wallac, Turku, Finland). The neutralizing Ab titer is determined as the highest serum dilution giving Ն50% inhibition of infection, relative to infection in the absence of serum.
ELISPOT assay for detection of Ad-specific, mouse ␥IFN (m␥IFN)-secreting splenocytes
Ninety-six-well nitrocellulose plates (Millipore, Molsheim, France) were coated by adding 100 l per well of a rat anti-m␥IFN mAb (Pharmingen, San Diego, CA, USA) diluted at 3 g/ml in carbonate buffer (15.7 mM NaHCO 3 , 15.7 mM Na 2 CO 3 ) and incubated overnight at 4°C. Plates were washed five times with DMEM 10% FCS and satured 2 h at 37°C with 100 l/well of DMEM 10% FCS. Splenocytes from C57Bl/6 mice were plated at a concentration of 10 6 cells/100 l/well. A non-replicative Ad vector devoid of a transgene expression cassette was added at a multiplicity of infection of 100. In each well, medium was supplemented with 6 units IL-2 (R&D Systems). Concanavalin A (5 g/ml)-stimulated splenocytes were used as positive controls (performed for each spleen). After 48 h incubation at 37°C, 5% CO 2 , plates were washed once with PBS and five times with PBS con-taining 0.05% Tween 20 (PBS-Tween). Wells were incubated with 0.3 g per 100 l of a biotin-conjugated rat anti-m␥IFN mAb (Pharmingen, San Diego, CA, USA) for 2 h at room temperature. Plates were then washed five times with PBS-Tween and alkaline-phosphatase-conjugated Extravidin (BioRad Laboratories, Hercules, CA, USA) diluted 1/5000 in PBS-Tween-1% FCS was added. After 45-min incubation, plates were washed five times with PBS-Tween and the presence of mIFN␥-secreting cells was revealed by adding 100 l per well of the substrate solution (AP Conjugate Substrate Kit, BioRad Laboratories). After 30 min, the substrate solution was discarded and the plates were washed with water and air-dried. Blue spots were counted using a stereomicroscope.
